Table 2.
Patient and Transplant Characteristics. (A) All autologous stem cell transplants (ASCTs) during the study period. (B) ASCTs with cryopreserved PBSC products containing a cumulative TNC dose of > 1.63 × 109/kg.
| (A) | |||
|---|---|---|---|
| Pre-policy change (n=325) |
Post-policy change (n=519) |
P-value | |
| Age at ASCT, years, median (range) | 53 (1–78) | 55 (0–74) | 0.02 |
| Male, n (%) | 230 (71) | 342 (66) | 0.14 |
| Weight, median (range) | 81.1 (10.6–165.0) | 81.8 (7.5–158.8) | 0.55 |
| Diagnosis, n (%) | |||
| Multiple myeloma | 118 (36) | 225 (43) | |
| Non-Hodgkin’s lymphoma/CLL | 119 (37) | 175 (34) | |
| Other Diagnoses | 88 (27) | 119 (23) | 0.12 |
| CD34 × 106/kg, median (range) | 6.29 (0.22–59.25) | 6.35 (0.81–87.04) | 0.49 |
| TNC × 109/kg, median (range) | 0.82 (0.09–8.65) | 0.92 (0.05–7.26) | 0.43 |
| Volume (mL)/kg/day, median (range) | 1.75 (0.26–9.27) | 1.68 (0.30–7.61) | 0.003 |
| Volume (mL) /kg total, median (range) | 1.80 (0.26–16.78) | 1.80 (0.30–10.49) | 0.88 |
| (B) | |||
|---|---|---|---|
| Pre-policy change (n=82) |
Post-policy change (n=125) |
P-value | |
| Age at ASCT, years, median (range) | 57 (2–75) | 60 (2–73) | 0.32 |
| Male, n (%) | 56 (68) | 73 (58) | 0.15 |
| Weight, median (range) | 78.9 (15.1–137.8) | 72.3 (14.8–121.7) | 0.69 |
| Diagnosis, n (%) | |||
| Multiple myeloma | 20 (24) | 45 (36) | |
| Non-Hodgkin’s lymphoma/CLL | 44 (54) | 61 (49) | |
| Other Diagnoses | 18 (22) | 19 (15) | 0.16 |
| CD34 × 106/kg, median (range) | 4.98 (1.11–25.8) | 5.00 (0.81–53.6) | 0.64 |
| TNC × 109/kg, median (range) | 2.66 (1.64–8.64) | 2.53 (1.63–7.26) | 0.90 |
| Volume (mL)/kg/day, median (range) | 4.54 (1.13–9.27) | 2.37 (1.00–7.61) | <0.0001 |
| Volume (mL)/kg total, median (range) | 5.29 (2.26–16.78) | 5.11 (2.00–10.49) | 0.81 |